21.38
0.69 (3.33%)
| Previous Close | 20.69 |
| Open | 20.76 |
| Volume | 470,502 |
| Avg. Volume (3M) | 555,657 |
| Market Cap | 1,016,858,432 |
| Price / Earnings (Forward) | 250.00 |
| Price / Sales | 12.58 |
| Price / Book | 3.46 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -11.86% |
| Operating Margin (TTM) | -5.09% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | 29.90% |
| Total Debt/Equity (MRQ) | 7.64% |
| Current Ratio (MRQ) | 4.73 |
| Operating Cash Flow (TTM) | 14.63 M |
| Levered Free Cash Flow (TTM) | 39.10 M |
| Return on Assets (TTM) | -0.79% |
| Return on Equity (TTM) | -2.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | BioLife Solutions, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -2.5 |
| Price Volatility | 1.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 2.84% |
| % Held by Institutions | 100.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cramer Rosenthal Mcglynn Llc | 31 Dec 2024 | 905,752 |
| 52 Weeks Range | ||
| Median | 32.00 (49.67%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Aug 2025 | 32.00 (49.67%) | Buy | 22.68 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AEBERSOLD SARAH | - | 25.65 | -219 | -5,617 |
| BERARD TODD | - | 25.65 | -10,354 | -265,580 |
| FOSTER KAREN A. | - | 25.65 | -413 | -10,593 |
| MATHEW ABY J. | - | 25.65 | -531 | -13,620 |
| WERNER SEAN | - | 25.65 | -111 | -2,847 |
| WICHTERMAN TROY | - | 25.65 | -590 | -15,134 |
| Aggregate Net Quantity | -12,218 | |||
| Aggregate Net Value ($) | -313,392 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 25.65 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BERARD TODD | Officer | 26 Aug 2025 | Automatic sell (-) | 354 | 25.65 | 9,080 |
| AEBERSOLD SARAH | Officer | 26 Aug 2025 | Automatic sell (-) | 219 | 25.65 | 5,617 |
| WICHTERMAN TROY | Officer | 26 Aug 2025 | Automatic sell (-) | 590 | 25.65 | 15,134 |
| WERNER SEAN | Officer | 26 Aug 2025 | Automatic sell (-) | 111 | 25.65 | 2,847 |
| FOSTER KAREN A. | Officer | 26 Aug 2025 | Automatic sell (-) | 413 | 25.65 | 10,593 |
| MATHEW ABY J. | Officer | 26 Aug 2025 | Automatic sell (-) | 531 | 25.65 | 13,620 |
| BERARD TODD | Officer | 25 Aug 2025 | Sell (-) | 10,000 | 25.65 | 256,500 |
| Date | Type | Details |
|---|---|---|
| 07 Aug 2025 | Announcement | BioLife Solutions Reports Second Quarter 2025 Financial Results |
| 28 Jul 2025 | Announcement | BioLife Solutions Makes Strategic Investment in Pluristyx |
| 24 Jul 2025 | Announcement | BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |